Process development's impact on Cost of Goods Manufactured (COGM)

BioProcess International

Volumn 8, Issue 3, 2010, Pages 48-55

  Han, Chae ^a   Nelson, Philip ^a   Tsai, Amos ^b  

^a AMGEN INC   (United States)

^b Amgen's Thousand Oaks Facility   (United States)

Author keywords

Chromatography; COGM; Manufacturing throughput; Raw materials; Run rate; Static modeling; Unit operations

Indexed keywords

ARTICLE; COLUMN CHROMATOGRAPHY; COST EFFECTIVENESS ANALYSIS; COST OF GOODS MANUFACTURED; PLANT BIOTECHNOLOGY; PLANT MODEL; PROCESS DEVELOPMENT; PROTEIN PROCESSING; PURIFICATION; QUALITY CONTROL;

EID: 77953430445     PISSN: 15426319     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (6)

1. Chadd HE, Chamow SC. Therapeutic Antibody Expression Technology. Curr. Opin. Biotechnol. 12(2), 2001: 188-194.
2. Sommerfeld S, Strube J, J. Challenges in Biotechnology Production: Generic Processes and Process Optimization for Monoclonal Antibodies. Chem Eng Proc. 44(10) 2005: 1123-1137.
3. Dowd C, van Reis R. Cost Reduction Strategies in Recovery Process Design. Proceedings of IBC's 4th International Conference on Production and Economics of Biopharmaceuticals; 14-15 November 2001, San Diego, CA.
4. SP Fulton, et al. Large-Scale Processing and High-Throughput Perfusion Chromatography. Bio/Technology 10(6) 1992: 635-639.
5. RG Harrison, et al. Bioseparations Science and Engineering. Oxford University Press, New York, NY, 2003; 319-371.
6. Petrides DP, Siletti CA. The Role of Process Simulation and Scheduling Tools in the Development and Manufacturing of Biopharmaceuticals. Proceedings of the 2004 Winter Simulation Conference, Ingalls R, et al. (Eds.); www.inform-sim.org/wsc04papers/274.pdf (accessed 1/22/10).